Checkpoint inhibitors seem safe against cancer in HIV patients
Previously, they were excluded from clinical trials
22nd February 2019
In HIV-infected patients with a variety of advanced cancers, immune-checkpoint inhibitors appear to be effective and add no new risks, according to a new systematic review.
As Dr Chul Kim of Georgetown University, in Washington, DC, said by email, using checkpoint inhibitors "for the treatment of advanced-stage cancer in patients with HIV infection was associated with no new safety signals," and "may be a safe and efficacious treatment option in this patient population."
